Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Short- and long-term impact of vaccination against cytomegalovirus: a modeling study

Fig. 3

Universal vaccination of females with a vaccine preventing (re-)infection and reactivation. a The incidence of cCMV. b The incidence of primary infections and re-infections/reactivations during the first 50 years after the start of vaccination of 25-year-old women. The proportion of effectively vaccinated women (vaccination coverage × vaccine efficacy) is 70%, and the duration of protection is 10 years. c The reduction in cCMV after 20 years for different vaccination ages (10, 25, and 50 years) and proportions of effectively vaccinated women

Back to article page